Sarepta Therapeutics Announces Second Quarter 2015 Financial Results and Recent Corporate Developments
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P, Nasdaq drop on tech selloff as concerns about hawkish Fed, AI spending mount
- Chip stocks plunge, but bargain-hunters stem losses in other tech names
- Oil prices steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Sarepta Therapeutic (SRPT) PT Raised to $47 at Baird; Increasingly Bullish on Risk/Reward
August 7, 2015 7:41 AM EDTBaird analyst Brian Skorney reiterated an Outperform rating and boosted his price target on Sarepta Therapeutic (NASDAQ: SRPT) to $47.00 (from $34.00), saying they are increasingly bullish on risk/reward.
Sarepta commented, "After spending time with management recently and hearing additional granularity on the... More
SunTrust Downgrades Sarepta Therapeutic (SRPT) to Neutral
August 7, 2015 7:07 AM EDTSunTrust Robinson Humphrey downgraded Sarepta Therapeutic (NASDAQ: SRPT) from Buy to Neutral with a price target of $33 (unchanged).
For an analyst ratings summary and ratings history on Sarepta Therapeutic click here. For more ratings news on Sarepta Therapeutic click here.
Shares of Sarepta Therapeutic closed at $34.63 yesterday.
... MoreSarepta Therapeutics (SRPT) Tops Q2 EPS by 20c
August 6, 2015 7:35 AM EDTSarepta Therapeutics (NASDAQ: SRPT) reported Q2 EPS of ($1.01), $0.20 better than the analyst estimate of ($1.21).
We made significant achievements from both a regulatory and clinical perspective this quarter and look to build on this momentum as we continue through the regulatory process for eteplirsen,... More
